Xeltis has today announced the appointment of clinical nephrology experts An De Vriese and Haimanot (Monnie) Wasse to its medical advisory board.
De Vriese is currently head of the division of nephrology and infectious disease in AZ Sint-Jan Brugge, in Brugge, Belgium and guest professor at Ghent University in Gent, Belgium, while Wasse serves as the interim chair of the department of internal medicine, and the chief of nephrology and director of interventional nephrology at the Rush University Medical Center in Chicago, USA. A press release by Xeltis has stated that both add considerable clinical nephrology expertise to the company’s medical advisory board and will work alongside current members to offer strategic and clinical guidance as Xeltis advances aXess towards commercialisation.
Eliane Schutte, chief executive officer of Xeltis said: “We are pleased that both De Vriese and Wasse have chosen to join our medical advisory board, bolstering our already stellar team of advisors. The appointments represent significant validation of the unique and promising nature of our technology from leading experts in the field. Their experience across nephrology and vascular access will be invaluable as we continue to progress aXess through its pivotal trials in the EU and US, with primary readouts for our EU pivotal trial expected in mid-2025.”
“It is an honour to join Xeltis’ MAB at such a pivotal time in the company’s development,” commented De Vriese. “I am truly excited by Xeltis’ innovative technology which, through its avoidance of the frequent reinterventions and infections associated with current treatment options, has the potential to transform patient outcomes for those with end-stage renal disease.”
On his recent appointment, Wasse stated: “I am familiar with the important work of Xeltis, having kept a keen eye on the continual clinical progress of its technology. aXess has an immensely promising medical profile, and I am proud to now be in a position to offer my expertise in interventional nephrology and vascular access to further the clinical development of this innovative technology.”
Currently, Xeltis is advancing pivotal trials in both the EU and the US for aXess; enrolment was recently completed in the EU while ten patients have now been implanted in the USA.
